Moderna has accomplished several significant milestones as per the latest events in the biotech sector. The company's Covid-19 vaccine has gained primary approval following successful trials. Moreover, the prospects are encouraging for a combined COVID and flu vaccine, which could greatly boost public health. The mRNA RSV vaccine for older adults has also received FDA approval. The US is reportedly close to finalizing a deal to fund a trial for Moderna's bird flu shot. A two-in-one flu and Covid vaccine by Moderna has passed advanced stages of testing. The company has also won a patent case against Pfizer-BioNtech in Europe. Phase III data promisingly indicate that Moderna's combination Covid-flu vaccine is better than the separate shots. The company is also expanding its personalized cancer treatments. Despite a minor fall in the past week, Moderna's shareholders are still seeing an 857% increase over five years.
Moderna MRNA News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Sun, 16 Jun 2024 15:22:22 GMT - Rating 8 - Innovation 7 - Information 9 - Rumor 5
